Neeraj Agarwal, MD on Phase 3 TITAN Study in High vs. Low Risk Patients with mCSPC @neerajaiims @huntsmancancer #prostatecancer

Neeraj Agarwal, MD @neerajaiims of @huntsmancancer discusses post-hoc review of data from the TITAN Phase 3 trial on time to second deterioration (PFS2) or death at any point for patients undergoing hormone versus taxane therapy following initial ERLEADA ® treatment efficacy and safety results in high- versus low-risk patients with mCSPC. 

#prostate #cancer #metastaticprostatecancer #TITAN #TITANstudy #PFS2 #HuntsmanCancer